1. Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
- Author
-
G. A. Dashyan, V. F. Semiglazov, P. V. Krivorot’ko, T. Yu. Semiglazova, E. E. Topuzov, R. M. Paltuev, K. Yu. Zernov, V. S. Apollonova, S. S. Ereshchenko, A. V. Petrova, E. K. Zhil’tsova, and O. A. Ivanova
- Subjects
Oncology ,t-dm1 ,medicine.medical_specialty ,Chemotherapy ,Systemic disease ,business.industry ,medicine.medical_treatment ,Obstetrics and Gynecology ,Gynecology and obstetrics ,medicine.disease ,Breast cancer ,her-2-positve breast cancer ,central nervous system metastases ,Internal medicine ,medicine ,RG1-991 ,Pharmacology (medical) ,Radiology, Nuclear Medicine and imaging ,Surgery ,business - Abstract
Brain metastases are detectable in 25–35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of investigations substantiating the use of anti-HER-2 targeting agents, as well as the innovative agent T-DM1 to treat brain metastases.
- Published
- 2016